Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Neurological Disorders and Stroke (NINDS) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00001208 |
Botulism is a severe form of food poisoning caused by bacteria. This bacteria produces several toxins one of which is botulinum toxin A. This toxin causes the symptoms of food poisoning. Small amounts of botulinum toxin A have been used to treat speech disorders such as stuttering and problems with the muscles of the eyes.
The study examines the effectiveness of botulinum toxin as treatment for a variety of movement disorders. The goals of the study are to refine the technique of treatment to provide the best results, to improve the understanding of how botulinum toxin works on movement disorders, and find other conditions that may be treatable with botulinum toxin.
In addition, researchers also plan to study the possible use of botulinum toxin F alone and in combination with botulinum toxin A in patients who do not respond to botulinum A toxin treatment. ...
Condition |
---|
Chorea Drug Induced Dyskinesia Movement Disorder Muscular Disease Tic Disorder |
Study Type: | Observational |
Official Title: | A Training Protocol for the Use of Botulinum Toxin in the Treatment of Neurological Disorders |
Estimated Enrollment: | 1000 |
Study Start Date: | November 1985 |
The efficacy of botulinum toxin (btx) has now been demonstrated for a variety of diseases associated with involuntary muscle spasms or movement. The application of botulinum toxin therapy to movement disorders requires treatment tailored to the individual patient and specific techniques of injection. This protocol 1) provides for training of physicians in the use of botulinum toxin and 2) allows us to provide botulinum toxin injections for patients participating in other studies on the physiology of sensorimotor systems and physiological effects of botulinum toxin.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Patients will be eligible for participation if they have a disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia.
EXCLUSION CRITERIA:
Patients will be excluded form participation if
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Study ID Numbers: | 850195, 85-N-0195 |
Study First Received: | November 3, 1999 |
Last Updated: | July 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00001208 |
Health Authority: | United States: Federal Government |
Spasmodic Torticollis Writer's Cramp Spasmodic Dysphonia Stuttering Oromandibular Dystonia |
Palatal Myoclonus Dystonia Essential Tremor Movement Disorders |
Dystonic Disorders Neurotoxicity Syndromes Dystonia Disorders of Environmental Origin Tics Signs and Symptoms Musculoskeletal Diseases Neuromuscular Diseases Movement Disorders Mental Disorders Mental Disorders Diagnosed in Childhood Myoclonus Essential Tremor Dyskinesia, Drug-Induced Spastic dysphonia |
Neurotoxicity syndromes Poisoning Central Nervous System Diseases Dyskinesia, drug induced Tic Disorders Muscle Cramp Tremor Dyskinesias Chorea Spasmodic dysphonia Torticollis Botulinum Toxins Muscular Diseases Drug Toxicity Benign essential tremor syndrome |
Pathologic Processes Disease Anti-Dyskinesia Agents Therapeutic Uses |
Nervous System Diseases Central Nervous System Agents Pharmacologic Actions |